Publications

Journal Article Ppublish 54 citations
Electronic publication date
August 9, 2022

View on Pubmed.gov 35621369 | View on doi.org 10.1111/ene.154...

Risk of intracranial meningioma with three potent progestogens: A population-based case-control study.

Search for publications in this journal Eur J Neurol - 29(9):2801-2809

Abstract

BACKGROUND AND PURPOSE

A dose-dependent association between the use of cyproterone acetate (CPA) and intracranial meningioma has been identified but data for other potent progestogens are scarce. The association was assessed between intracranial meningioma surgery and exposure to three potent progestogens: CPA (≥25 mg/day), nomegestrol acetate (NOMAC) (3.75-5 mg/day) and chlormadinone acetate (CMA) (2-10 mg/day).

METHODS

In this nationwide population-based case-control study, cases underwent surgery for intracranial meningioma in France from 2009 to 2018. They were matched to five control subjects for sex, year of birth and area of residence. Progestogen exposure was defined as progestogen use within the year before surgery for cases or the same date for their controls.

RESULTS

In total, 25,216 cases were included (75% women, median age 58 years). Progestogen exposure was noted for 9.9% of cases (2497/25,216) and 1.9% (2382/126,080) of controls, with an odds ratio (OR) of 6.7 (95% confidence interval [CI] 6.3-7.1). The OR was 1.2 (1.0-1.4) for short-term use (<1 year) and 9.5 (8.8-10.2) for prolonged use. A strong association was identified for prolonged use of CPA (OR = 22.7, 95% CI 19.5-26.4), NOMAC (OR = 6.5, 95% CI 5.8-7.2) and CMA (OR = 4.7, 95% CI 4.5-5.3). Progestogen exposure increased the risk of meningioma for all histological grades and anatomical sites, particularly for the anterior and middle skull base: OR = 35.7 (95% CI 26.5-48.2) and 23.9 (95% CI 17.8-32.2) for CPA. The estimated number of attributable cases was 2124 (95% CI 2028-2220) (212/year).

CONCLUSION

A strong association between prolonged exposure to potent progestogens and surgery for meningioma was observed. The risk increased from CMA to NOMAC to CPA. Individuals should be informed of this risk.

References

Endocrinology. 2022 Feb 1;163(2):

Neurosurg Rev. 2022 Apr;45(2):1691-1699

Neurosurgery. 2021 Jul 15;89(2):308-314

Acta Neurochir (Wien). 2019 Dec;161(12):2553-2561

Cited by 54 citations (total)

Journal Article Review

Meningioma: Novel Diagnostic and Therapeutic Approaches.

Electronic publication date March 28, 2025

Search for publications in this journal Biomedicines

Carlen A Yuen [...] David O Kamson et al.

: Meningiomas are the most common intracranial tumors. Surgery and radiation therapy are the cornerstones of treatment and no standard...

Meta-Analysis Systematic Review Journal Article

The Association Between Meningioma and Breast Cancer: A Systematic Review and Meta-analysis.

Electronic publication date June 19, 2023

Search for publications in this journal JAMA Netw Open

Aurélie Degeneffe [...] Florence Lefranc et al.

Importance

A potential relationship between meningioma and breast cancer was suggested 70 years ago. However, to date, no conclusive evidence is...

Conflict of interest statement

No conflict of interest statement provided.

MeSH

Specialties

Substances

Copyright

© 2022 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.